NDAINTRAVENOUSSOLUTION
Approved
Feb 2011
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
TOPOTECAN HYDROCHLORIDE (topotecan) by Pfizer is single-strand breaks. Approved for small cell lung cancer, ovarian cancer, fallopian tube cancer and 1 more indications. First approved in 2011.
Drug data last refreshed 23h ago
Mechanism of Action
single-strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents re-ligation of these single-strand breaks. The cytotoxicity of topotecan is thought to be due to double-strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex…
Indications (4)
Worked on TOPOTECAN HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.